,
,
/13 (30,8) 8/22 (36,4) 6/16 (37,5) 5/17 (29,4) Prise en charge initiale Palliative ,
,
, Distribution des paramètres cliniques et pathologiques en fonction de la densité de TAMS et de leur expression de PD-L1 Phénotype non-GC Oui, vol.7
,
,
, IELSG: International Extranodal Lymphoma Study Group
Comparaison des groupes IELSG faible+intermediaire versus élevé ,
,
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer. 1 mars, vol.136, issue.5, pp.359-386, 2015. ,
WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview, Pathologica. juin, vol.102, issue.3, pp.83-90, 2010. ,
WHO classification of tumours of haematopoietic and lymphoid tissues, 2017. ,
Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues, Ann Diagn Pathol. 1 févr, vol.38, pp.6-10, 2019. ,
Diffuse large B-cell lymphoma, Pathology (Phila). janv, vol.50, issue.1, pp.74-87, 2018. ,
A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy, Clin Cancer Res. 1 sept, vol.15, issue.17, pp.5494-502, 2009. ,
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood. 1 janv, vol.103, issue.1, pp.275-82, 2004. ,
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med. 24 janv, vol.346, issue.4, pp.235-277, 2002. ,
The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now, Crit Rev Oncol Hematol. 1 mai, vol.113, pp.52-62, 2017. ,
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone, J Clin Oncol, vol.30, issue.28, pp.3452-3461, 2012. ,
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial, Parma Group. Blood, vol.92, issue.10, pp.3562-3570, 1998. ,
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study, Haematologica. févr, vol.98, issue.2, pp.255-63, 2013. ,
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP, Mod Pathol Off J U S Can Acad Pathol Inc. déc, vol.28, issue.12, pp.1555-73, 2015. ,
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid, 2008. ,
Primary central nervous system lymphoma, Ther Adv Neurol Disord, vol.11, p.1756286418793562, 2018. ,
The role of ABCB1 polymorphism as a prognostic marker for primary central nervous system lymphoma, Ann Hematol. 6 févr, 2019. ,
, J Clin Oncol Off J Am Soc Clin Oncol. 20 juill, vol.35, issue.21, pp.2410-2418, 2017.
, Curr Hematol Malig Rep. sept, vol.9, issue.3, pp.243-53, 2014.
Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China, Chin J Cancer Res Chung-Kuo Yen Cheng Yen Chiu. févr, vol.31, issue.1, pp.152-61, 2019. ,
Characterization of genomic alterations in primary central nervous system lymphomas, J Neurooncol. 1 déc, vol.140, issue.3, pp.509-526, 2018. ,
Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience, J Clin Oncol Off J Am Soc Clin Oncol. 15 janv, vol.21, issue.2, pp.266-72, 2003. ,
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model, J Clin Oncol Off J Am Soc Clin Oncol. 20 déc, vol.24, issue.36, pp.5711-5716, 2006. ,
The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1, Neuropathol Off J Jpn Soc Neuropathol. avr, vol.38, issue.2, pp.125-159, 2018. ,
A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases, Blood. 1 janv, vol.107, issue.1, pp.190-196, 2006. ,
Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma, Br J Haematol. févr, vol.184, issue.3, pp.348-63, 2019. ,
Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment, Leuk Lymphoma, vol.49, issue.1, pp.43-51, 2008. ,
Novel agents for primary central nervous system lymphoma: evidence and perspectives, Blood. 16 août, vol.132, issue.7, pp.681-689, 2018. ,
The emerging role of immune checkpoint inhibition in malignant lymphoma, Haematologica, vol.102, issue.1, pp.30-42, 2017. ,
Novel immunotherapies in lymphoid malignancies, Nat Rev Clin Oncol. janv, vol.13, issue.1, pp.25-40, 2016. ,
Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenasepositive cells in primary diffuse large B-cell lymphoma of the central nervous system, Disponible sur, vol.7, 2018. ,
Enhancement of antitumor immunity by CTLA-4 blockade, Science. 22 mars, vol.271, issue.5256, pp.1734-1740, 1996. ,
Targeting the programmed death-1 pathway in lymphoid neoplasms, Cancer Treat Rev. mars, vol.54, pp.99-109, 2017. ,
The B7 family of immune-regulatory ligands, Genome Biol, vol.6, issue.6, p.223, 2005. ,
PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas, Ann Hematol. 1 févr, vol.97, issue.2, pp.229-266, 2018. ,
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large Bcell lymphoma, Blood, vol.116, issue.17, pp.3268-77, 2010. ,
PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy, J Cell Physiol. août, vol.234, issue.10, pp.16824-16861, 2019. ,
Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas, Hum Pathol, vol.54, pp.17-24, 2016. ,
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma, Blood, vol.126, pp.2193-201, 2015. ,
Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas, Pathol -Res Pract. 1 avr, vol.214, issue.4, pp.507-519, 2018. ,
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review, Lung Cancer Amst Neth, vol.112, pp.200-215, 2017. ,
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy, Tumour Biol J Int Soc Oncodevelopmental Biol Med. avr, vol.37, issue.4, pp.4251-61, 2016. ,
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clin Cancer Res Off J Am Assoc Cancer Res, vol.20, pp.5064-74, 2014. ,
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med. 28 juin, vol.366, issue.26, pp.2443-54, 2012. ,
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med. 22 janv, vol.372, issue.4, pp.311-320, 2015. ,
Novel therapeutic agents for relapsed classical Hodgkin lymphoma, Br J Haematol. janv, vol.184, issue.1, pp.105-117, 2019. ,
MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas, Blood Adv. 5 févr, vol.3, issue.3, pp.375-83, 2019. ,
PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL), Clin Neuropathol. févr, vol.33, issue.1, pp.42-51, 2014. ,
PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival, Hematol Oncol. déc, vol.35, issue.4, pp.487-96, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01794739
Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study, Anticancer Res, vol.37, issue.10, pp.5655-66, 2017. ,
The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma, J Clin Exp Hematop, vol.58, issue.2, pp.95-101, 2018. ,
Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma, Oncotarget. 14 août, vol.8, issue.50, pp.87317-87345, 2017. ,
Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma, Leuk Lymphoma. 11 juin, pp.1-10, 2019. ,
High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system, Oncoimmunology, vol.8, issue.9, p.1626653, 2019. ,
Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study, Chin J Cancer. déc, vol.36, issue.1, p.94, 2017. ,
Targetable genetic features of primary testicular and primary central nervous system lymphomas, Blood. 18 févr, vol.127, issue.7, pp.869-81, 2016. ,
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma, Blood, vol.08, issue.23, pp.3071-3074, 2017. ,
Tumor-Associated Macrophages as Target for Antitumor Therapy, Arch Immunol Ther Exp (Warsz), vol.66, issue.2, pp.97-111, 2018. ,
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies, J Pathol. mars, vol.196, issue.3, pp.254-65, 2002. ,
Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer, Cell Cycle Georget Tex, vol.17, issue.4, pp.428-466, 2018. ,
Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy, Clin Cancer Res Off J Am Assoc Cancer Res. 19 mars, 2019. ,
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation, J Leukoc Biol, vol.86, issue.5, pp.1065-73, 2009. ,
Tumor-Associated Macrophages as Treatment Targets in Oncology, Nat Rev Clin Oncol. juill, vol.14, issue.7, pp.399-416, 2017. ,
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma, N Engl J Med. 11 mars, vol.362, issue.10, pp.875-85, 2010. ,
The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma, Leuk Lymphoma, vol.52, issue.10, pp.1913-1922, 2011. ,
High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly 48 correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma, Hematol Oncol. juin, vol.33, issue.2, pp.110-112, 2015. ,
An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Leuk Lymphoma, vol.55, issue.11, pp.2466-76, 2014. ,
CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma, Am J Clin Pathol. mars, vol.141, issue.3, pp.381-388, 2014. ,
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial, Blood, vol.120, issue.16, pp.3280-3287, 2012. ,
Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes, Oncotarget. 17 janv, vol.8, issue.3, pp.5414-5439, 2017. ,
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial, Haematologica. févr, vol.100, issue.2, pp.238-283, 2015. ,
Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study, Br J Haematol. mars, vol.112, issue.4, pp.945-954, 2001. ,
T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma, Haematologica. févr, vol.104, issue.2, pp.338-384, 2019. ,
CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemoimmunotherapy, Am J Hematol. avr, vol.88, issue.4, pp.273-279, 2013. ,
CD4+ T-Cell Immune Response to Large B-Cell Non-Hodgkin's Lymphoma Predicts Patient Outcome, J Clin Oncol. 1 févr, vol.19, issue.3, pp.720-726, 2001. ,
The role of CD4+ T cell responses in antitumor immunity, Curr Opin Immunol, vol.10, issue.5, pp.588-94, 1998. ,
CD4 T Cells and Their Role in Antitumor Immune Responses, J Exp Med. 1 mars, vol.189, issue.5, pp.753-759, 1999. ,
Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies, Blood, vol.114, issue.16, pp.3367-75, 2009. ,
Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immuneprivileged sites: the importance of apoptosis and immunomodulatory pathways, J Pathol, vol.216, issue.2, pp.209-226, 2008. ,
Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart, Histopathology, vol.67, issue.5, pp.625-660, 2015. ,
Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis, J Immunother Cancer, vol.6, issue.1, p.20, 2018. ,
Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells, Int J Cancer, vol.15, issue.10, pp.2300-2312, 2010. ,
M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma, J Clin Exp Hematop JCEH, vol.51, issue.2, pp.93-102, 2011. ,
Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma, Ann Hematol. sept, vol.89, issue.9, pp.889-96, 2010. ,
Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.11, issue.7, pp.976-88, 2016. ,
PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis, Am J Surg Pathol. févr, vol.34, issue.2, pp.178-89, 2010. ,
Several immune escape patterns in non-Hodgkin's lymphomas, Oncoimmunology. août, vol.4, issue.8, p.1026530, 2015. ,
PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Am J Surg Pathol, vol.42, issue.3, pp.326-360, 2018. ,
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome, J Clin Oncol Off J Am Soc Clin Oncol, vol.10, issue.23, pp.2690-2697, 2016. ,
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies, Clin Cancer Res Off J Am Assoc Cancer Res. 1 juill, vol.19, issue.13, pp.3462-73, 2013. ,
Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets, Am J Surg Pathol. juill, vol.41, issue.7, pp.998-1004, 2017. ,
Les immune-checkpoints dans les hémopathies, Ann Pathol. 1 févr, vol.37, issue.1, pp.101-111, 2017. ,
Multiinstitutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer, JAMA Oncol. 1 août, vol.3, issue.8, pp.1051-1059, 2017. ,
The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis, BMC Cancer. 27 mars, vol.19, issue.1, p.273, 2019. ,
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas, Blood, vol.16, issue.24, pp.3026-3060, 2016. ,
Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas, Histopathology. juin, vol.68, issue.7, pp.1079-89, 2016. ,
Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma, Blood. 27 mars, vol.123, issue.13, pp.2062-2067, 2014. ,
Oncogenically active MYD88 mutations in human lymphoma, Nature. 3 févr, vol.470, issue.7332, pp.115-124, 2011. ,
Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines, J Clin Exp Hematop JCEH. 5 juill, vol.57, issue.1, pp.21-26, 2017. ,
An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma, Cancer Sci, vol.107, issue.11, pp.1696-704, 2016. ,
Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma, Acta Neuropathol (Berl). déc, vol.122, issue.6, pp.791-793, 2011. ,
Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation, Blood. 1 mars, vol.103, issue.5, pp.1869-75, 2004. ,
Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas, Clin Cancer Res Off J Am Assoc Cancer Res, vol.18, pp.5203-5214, 2012. ,
Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type, J Invest Dermatol. nov, vol.138, issue.11, pp.2365-76, 2018. ,
PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma, Haematologica. nov, vol.103, issue.11, pp.1908-1922, 2018. ,
Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma, Curr Hematol Malig Rep. déc, vol.13, issue.6, pp.543-54, 2018. ,
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study, J Clin Oncol Off J Am Soc Clin Oncol. 20 févr, vol.37, issue.6, pp.481-490, 2019. ,
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study, J Clin Oncol Off J Am Soc Clin Oncol, vol.10, issue.23, pp.2698-704, 2016. ,
Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model, Br J Haematol. nov, vol.183, issue.4, pp.674-682, 2018. ,
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.515, issue.7528, pp.563-570, 2014. ,
A dendritic-cellderived C-C chemokine that preferentially attracts naive T cells, Nature. 12 juin, vol.387, issue.6634, pp.713-720, 1997. ,
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s, J Exp Med. 5 janv, vol.187, issue.1, pp.129-163, 1998. ,
Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells, Cancer Med. déc, vol.7, issue.12, pp.6051-63, 2018. ,
Adoptive therapy with CD8+ T cells: it may get by with a little help from its friends, J Clin Invest, vol.110, issue.10, pp.1415-1422, 2002. ,
The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy<sup/>, Leuk Lymphoma, vol.58, issue.5, pp.1144-52, 2017. ,
High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis, J Pathol. juill, vol.206, issue.3, pp.328-364, 2005. ,
The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma, Medicine, vol.96, issue.15, p.6398, 2017. ,
Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment: clinical features and survival impact, Sci Rep, vol.07, issue.1, p.10813, 2017. ,
PD-1 expression on the surface of peripheral blood CD4+ T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma, Cancer Med, vol.5, issue.11, pp.3077-84, 2016. ,
Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma, Virchows Arch Int J Pathol. sept, vol.465, issue.3, pp.351-359, 2014. ,
Il a été rapporté une association entre la survie et certains éléments du microenvironnement tumoral, comme les lymphocytes infiltrant la tumeur (TILs) et les macrophages associés à la tumeur (TAMs), dans les LBDGC, mais dans les LBDGC-SNC, leur composition et leur impact pronostique sont insuffisamment connus, Haematologica, vol.101, issue.10, pp.1144-58, 2016. ,
, L'objectif de ce travail est de définir la composition du microenvironnement tumoral et de caractériser la voie PD-1/PD-L1 dans les LBDGC-SNC
, Matériel et méthodes : 57 cas de patients atteints de LBDGC-SNC avec du matériel tumoral exploitable ont été étudiés après recueil des données cliniques. Des examens immunohistochimiques ont été réalisés pour analyser les TAMs (CD68, CD163), les TILs (CD3, CD4, CD8, PD-1) et les cellules tumorales (double marquage PAX5/PD-L1, PD-L1). Le gène PD-L1 a été étudié par hybridation in situ en fluorescence (FISH)
, La translocation du gène PD-L1 était une altération cytogénétique récurrente dans les LBDGC-SNC (8/47, 17%) et était corrélée à une expression de PD-L1 par les cellules tumorales, Résultats : Le double marquage PAX5/PD-L1 a identifié une expression de PD-L1 par les cellules tumorales dans 17,5% des cas (10/57)
La majorité des TAMs exprimaient PD-L1 et la majorité des TILs exprimaient PD-1. La densité des TAMs et des TILs, ainsi que l'expression de PD-L1 par les cellules tumorales, n'étaient pas associée à la survie. En revanche, l'expression de PD-1 par les TILs et de PD-L1 par les TAMs, étaient corrélées à un meilleur pronostic. Conclusion : Ces résultats suggèrent que la composition du microenvironnement tumoral et la voie PD-1/PD-L1 jouent un rôle important dans la pathogenèse des LBDGC-SNC et apportent de nouvelles perspectives ,
, Mots clés : Lymphomes B diffus à grandes cellules, Système nerveux central, p.1